A 6-year-old girl with newly diagnosed acute lymphoblastic leukemia (ALL) has achieved complete remission after induction chemotherapy. Her initial bone marrow showed t(12;21) translocation. Which is the most appropriate investigation to monitor treatment response and guide intensification of therapy?

## Minimal Residual Disease (MRD) Monitoring in Childhood ALL ### Definition and Clinical Significance **Key Point:** Minimal residual disease (MRD) detection is the most powerful independent prognostic factor in childhood ALL and is the investigation of choice for monitoring treatment response and guiding therapy intensification. **High-Yield:** MRD is defined as leukemic cells at a level of <0.01% (1 in 10,000 cells) and is undetectable by morphology but detectable by: - Flow cytometry (most common, ~10^-4 sensitivity) - PCR-based methods (highest sensitivity, ~10^-6) - Digital PCR ### Why MRD Monitoring Is Superior | Parameter | Morphology | Peripheral Blood | MRD by Flow | |---|---|---|---| | **Sensitivity** | ~10^-2 (1%) | ~10^-2 | ~10^-4 | | **Timing** | At diagnosis, end of induction | Continuous | End of induction, consolidation | | **Prognostic value** | Moderate | Poor | Excellent (strongest independent predictor) | | **Guides therapy** | No | No | Yes (risk stratification) | ### MRD-Based Risk Stratification 1. **MRD-negative at end of induction** (< 0.01%) → Standard/low-intensity therapy 2. **MRD-positive at end of induction** (≥ 0.01%) → High-risk; requires therapy intensification 3. **MRD-positive at consolidation** → Very high-risk; consider stem cell transplantation **Clinical Pearl:** The t(12;21) translocation (TEL-AML1) is a favorable prognostic marker, but even favorable-risk patients with MRD positivity require intensification. MRD status overrides cytogenetic risk category in treatment decisions. **Mnemonic — MRD Timing:** **EIC** = End of Induction and Consolidation phases are critical MRD assessment points. ### Limitations of Other Investigations - **Repeat bone marrow aspiration every 2 weeks:** Unnecessary, invasive, and morphology cannot detect MRD - **Peripheral blood blast count:** Insensitive; blasts may not appear in PB even with significant marrow disease - **Karyotyping at each phase:** Cytogenetics is static; it does not change with treatment and is not used for response monitoring **High-Yield:** Modern ALL protocols use MRD at end of induction (day 28–35) and end of consolidation (week 12–16) to stratify risk and guide intensification decisions. [cite:Park 26e Ch 12; Harrison 21e Ch 110]